The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients

Antiviral Therapy

Volumn 9, Issue 5, 2004, Pages 753-761

  Yasuda, Julie M ^a   Miller, Chris ^a   Currier, Judith S ^d   Forthal, Donald N ^e   Kemper, Carol A ^f   Beall, Gildon N ^g   Tilles, Jeremiah G ^e   Capparelli, Edmund V ^b   McCutchan, J Alien ^b   Haubrich, Richard H ^b,c  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CCTG Data and Biostatistical Unit   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^g Harbor Clara Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; ARTICLE; CONCENTRATION RESPONSE; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINASE INHIBITION; RETROSPECTIVE STUDY; RNA ANALYSIS; SELF REPORT; TREATMENT OUTCOME;

ADULT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RNA, VIRAL;

EID: 7244221845     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338:853-860.
2. Decks SG. Determinants of virological response to antiretroviral therapy: implications for long-term strategies. Clinical Infectious Diseases 2000; 30(Suppl. 2):S177-184.
3. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P & Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-868.
4. Deeks SG, Barbour JD, Martin JN, Swanson MS & Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. Journal of Infectious Diseases 2000; 181:946-953.
5. Lucas GM, Chaisson RE & Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine 1999; 131:81-87.
6. Mathews C, Haubrich R, Barber E & Havlir D. Patterns and prognostic implications of prior antiretroviral therapy (ART) at UCSD Owen Clinic: 1996-1999. 7th Conference on Retroviruses & Opportunistic Infections. 30 January-2 February 2000, San Francisco, Calif., USA. Abstract 762.
7. Acosta E, Havlir D, Richman D, Zhou X, Hirsch M, Collier A, Tebas P & Sommadossi J-P. Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected patients receiving ZDV and 3TC. 7th Conference on Retroviruses & Opportunistic Infections. 30 January-2 February 2000, San Francisco, Calif., USA. Abstract 455.
8. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F & Brun-Vézinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Journal of the American Medical Association 2000; 283:205-211.
9. Garraffo R. Independent benefit of sufficient drug levels and genotypic analysis in salvage therapy: pharmacological data of the viradapt study. 39th Interscience Conference on Antimicrobial Agents & Chemotherapy. 26-29 September 1999, San Francisco, Calif., USA. Abstract 1166.
10. Powderly WG, Saag MS, Chapman S, Yu G, Quart B & Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13:1873-1880.
11. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD & Ledergerber B. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. Journal of the American Medical Association 2001; 286:2560-2567.
12. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM & Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000; 133:21-30.
13. Mannheimer S, Friedland G, Matts J, Child C & Chesney M. The consistency of adherence to antiretroviral therapy-predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases 2002; 34:1115-1121.
14. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, Buono D, Eckholdt H, Howard AA & Schoenbaum EE. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clinical Infectious Diseases 2001; 33:1417-1423.
15. Bangsberg DR, Bronstone A, Chesney MA & Hecht FM. Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice. Journal of Acquired Immune Deficiency Syndromes 2002; 31(Suppl. 3):S107-111.
16. Haubrich RH, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dube MP, Hwang J, Leedom JM, Tilles J & McCutchan JA. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clinical Infectious Diseases 2001; 33:1060-1068.
17. Wu EY, Wilkinson 2nd JM, Naret DG, Daniels VL, Williams LJ, Khalil DA & Shetty BV. High-performance liquid Chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. Journal of Chromatography. B, Biomedical Sciences & Applications 1997; 695:373-380.
18. Capparelli E. Time of first morning dose of protease inhibitor drugs in HIV-infected patients. 2001: unpublished data.
19. Tuldra A, Ferrer MJ, Fumaz CR, Bayes R, Paredes R, Burger DM & Clotet B. Monitoring adherence to HIV therapy. Archives of Internal Medicine 1999; 159:1376-1377.
20. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beau GN, Johnson D, Dube MP, Hwang JY & McCutchan JA. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. AIDS 1999; 13:1099-1107.
21. Tebas P, Royal M, Fichtenbaum C, Blutman J, Arens M, Horgan M & Powderly W. Relationship between adherence to HAART and disease state. 5th Conference on Retroviruses & Opportunistic Infections. 1-5 February 1998, Chicago, Ill., USA. Abstract 149.
22. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337:725-733.
23. Golin C, Liu H, Hays R, Ickovics J, Beck K, Miller L, Kaplan A & Wenger N. Self-reported adherence to protease inhibitors substantially overestimates an objective measure. 6th Conference on Retroviruses & Opportunistic Infections. 31 January-4 February 1999, Chicago, Ill., USA. Abstract 95.
24. Murri R, Ammassari A, Gallicano K, De Luca A, Cingolani A, Jacobson D, Wu AW & Antinori A. Patient-reported nonadherence to HAART is related to protease inhibitor levels. Journal of Acquired Immune Deficiency Syndromes 2000; 24:123-128.
25. Haubrich R, Lalezari J, Follansbee SE, Gill MJ, Hirsch M, Richman D, Mildvan D, Burger HU, Beattie D, Donatacci L & Salgo MP. Improved survival and reduced clinical progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Therapy 1998; 3:33-42.
26. Acosta EP & Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Research & Human Retroviruses 2002; 18:825-834.